NEW YORK, January 19, 2015 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including E2open (NASDAQ: EOPN), Baker Hughes (NYSE: BHI), Goldman Sachs (NYSE: GS), Altisource Portfolio (NASDAQ: ASPS), and Depomed (NASDAQ: DEPO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
EOPN Research Report: ( http://get.analystsreview.com/pdf/?c=E2open&d=19-Jan-2015&s=EOPN ),
BHI Research Report: ( http://get.analystsreview.com/pdf/?c=Baker%20Hughes&d=19-Jan-2015&s=BHI ),
GS Research Report: ( http://get.analystsreview.com/pdf/?c=Goldman%20Sachs&d=19-Jan-2015&s=GS ),
ASPS Research Report: ( http://get.analystsreview.com/pdf/?c=Altisource%20Portfolio&d=19-Jan-2015&s=ASPS ),
DEPO Research Report: ( http://get.analystsreview.com/pdf/?c=Depomed&d=19-Jan-2015&s=DEPO ).
Analyst Update: Strategic Review, Acquisitions, Corporate Update, and Quarterly Earnings
Reviewed by: Rohit Tuli, CFA®
The U.S. market snapped its five-day long losing streak on Friday, helped by rebound in the energy shares and a jump in the consumer sentiment index to 11-year high levels. The University of Michigan preliminary consumer sentiment index for January 2015 rose to 98.2, beating the median forecast of 94.1 that came from economists surveyed by Bloomberg. Energy stocks rallied sharply on Friday, following a rise in the oil prices, helping the S&P 500 index gain 1.34% to close at 2,019.42. The Dow Jones Industrial Average rose 1.10% to close at 17,511.57, and the Nasdaq Composite gained 1.39% to close at 4,634.38. Meanwhile, European equity markets closed mostly higher on Friday, while Swiss market remained under pressure after the Swiss National Bank's move to scrap its three-year old ceiling on franc. In Asia, the markets ended mostly lower as investors fled to safe-haven assets after the Swiss central bank's move.
Shares of E2open Inc. (E2open) rallied nearly 23% on Friday, January 16, after Wall Street Journal reported that the California-based software solutions provider is reviewing strategic options, including a sale. According to the report dated January 15, 2015, E2open is working with advisers at Bank of America Corp. as part of the process. Know more about E2open's strategic review and the subsequent market reaction in our detailed research report.
Baker Hughes Inc. (Baker Hughes) issued a regulatory filing to disclose that activist hedge fund ValueAct Capital has acquired a 5.1% stake in the Company. The move comes soon after Baker Hughes agreed to be acquired by Halliburton Co. in a cash-and-stock deal valued at around $34.6 billion. Continue reading about Baker Hughes' the acquisition related development in our exclusive research report.
Goldman Sachs Group Inc. (Goldman Sachs) reported fourth quarter 2014 net income at $2.2 billion, or $4.38 per diluted share, compared to $2.3 billion, or $4.60 per diluted share, in the year ago period. Goldman Sachs' Q4 2014 net income beat the average estimates of $4.32 per share in a Reuters' poll of analysts. To continue reading on Goldman Sachs' performance in the fourth quarter, please download our research report.
Altisource Portfolio Solutions S.A.'s (Altisource Portfolio) management team told investors on Friday, January 16, that the possibility of suspension of its former parent company Ocwen Financial's mortgage license in California is "very low." The statement led Altisource Portfolio's stock rally nearly 51% on Friday. Know more about the Altisource Portfolio's investor presentation, including the Company's earnings outlook, in our research report.
Shares of Depomed, Inc. (Depomed) jumped over 14% on Friday after the Company announced that it has entered into an agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The deal will make NUCYNTA the flagship asset in Depomed's portfolio of pain and neurology specialty pharmaceuticals. To know more about Depomed's agreement and its potential impact on the Company's earnings, please read our exclusive research report.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review